Frazier Life Sciences XI Buys $10M of ATTO Stock at $17, Converts Preferred Shares

summarizeSummary

Frazier Life Sciences XI, a 10% owner of Attovia Therapeutics, purchased $10 million of common stock at $17.00 per share and converted preferred shares into 5.49 million common shares upon the IPO closing.

check_boxKey Events · Ownership and Investor Activity · ATTO

• $10M Open-Market Purchase

  Frazier Life Sciences XI bought 588,235 shares at $17.00 each, totaling $9,999,995, on August 6, 2026.

• Preferred Stock Conversion

  Four series of preferred stock (A-1, A-2, B, C) automatically converted into 5,490,629 common shares upon the IPO closing, at a 9.29:1 ratio.

• Post-Transaction Holdings

  After the purchase and conversions, Frazier Life Sciences XI directly holds 6,154,213 shares of Attovia common stock.

• Purchase Near 52-Week Low

  The $17.00 purchase price is below the current $20.56 and near the 52-week low of $19.63, suggesting the investor sees value at depressed levels.

auto_awesomeAnalysis · ATTO · Life Sciences

Frazier Life Sciences XI, a 10% owner, made a $10 million open-market purchase of Attovia Therapeutics common stock at $17.00 per share — a price below the current $20.56 and near the 52-week low. The purchase is accompanied by the automatic conversion of four series of preferred stock into 5.49 million common shares upon the IPO closing, bringing total post-transaction holdings to 6.15 million shares. While the conversion is mechanical, the cash purchase signals conviction from a major institutional investor at a depressed valuation, especially given the stock's proximity to its 52-week low.